Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation
- PMID: 7509075
- PMCID: PMC43187
- DOI: 10.1073/pnas.91.4.1500
Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation
Abstract
We have shown that members of the erbB family undergo homodimer and heterodimer formation. The rat p185c-neu and the epidermal growth factor receptor (EGFR) can associate into an active heterodimeric tyrosine kinase. Overexpression of these two receptors also results in a transformed phenotype. We now show that mutant Neu proteins resulting from a point mutation at the ATP-binding site (N757) or cytoplasmic domain deletions (N691stop) are still able to undergo EGF-induced heterodimerization with EGFR. Analysis of heterodimer formation between EGFR and truncated Neu proteins revealed that heterodimerization is preferred over homodimerization of EGFR. N757 can be transphosphorylated by associated EGFR upon EGF stimulation. However, the heterodimer composed of EGFR and N691stop is kinase inactive. These results provided evidence that the Neu ectodomain is sufficient to associate with EGFR physically, and the cytoplasmic domain interaction is required for heterodimeric kinase activation, indicating that Neu/c-erbB2 is not just a simple substrate for EGFR but a transactivator as well.
Similar articles
-
Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.Oncogene. 1994 May;9(5):1507-14. Oncogene. 1994. PMID: 7908733
-
p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1330-4. doi: 10.1073/pnas.89.4.1330. Proc Natl Acad Sci U S A. 1992. PMID: 1346931 Free PMC article.
-
Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses.J Biol Chem. 1992 Apr 25;267(12):8056-63. J Biol Chem. 1992. PMID: 1349015
-
ErbB Receptors and Cancer.Methods Mol Biol. 2017;1652:3-35. doi: 10.1007/978-1-4939-7219-7_1. Methods Mol Biol. 2017. PMID: 28791631 Review.
-
Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.J Cell Biochem. 1993 Sep;53(1):61-73. doi: 10.1002/jcb.240530108. J Cell Biochem. 1993. PMID: 7901229 Review.
Cited by
-
Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.J Comput Aided Mol Des. 2020 Mar;34(3):293-303. doi: 10.1007/s10822-019-00270-4. Epub 2019 Dec 11. J Comput Aided Mol Des. 2020. PMID: 31828486
-
The role of hormones, growth factors and their receptors in pituitary tumorigenesis.Brain Pathol. 2001 Jul;11(3):356-70. doi: 10.1111/j.1750-3639.2001.tb00405.x. Brain Pathol. 2001. PMID: 11414477 Free PMC article. Review.
-
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.Mol Cell Biol. 2014 Mar;34(6):965-77. doi: 10.1128/MCB.01605-13. Epub 2013 Dec 30. Mol Cell Biol. 2014. PMID: 24379439 Free PMC article.
-
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.J Biol Chem. 2011 May 27;286(21):18756-65. doi: 10.1074/jbc.M110.206193. Epub 2011 Mar 30. J Biol Chem. 2011. PMID: 21454582 Free PMC article.
-
Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11772-7. doi: 10.1073/pnas.0801463105. Epub 2008 Aug 13. Proc Natl Acad Sci U S A. 2008. PMID: 18701712 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous